Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Ardelyx Inc
ARDX | US
5.96
USD-0.34
-5.40%
ARDX | US
About Ardelyx Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/04/2026
Close
5.96
Open
6.33
High
6.37
Low
5.88
Ardelyx Inc. a biopharmaceutical company discovers develops and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis or hyperphosphatemia; RDX013 a potassium secretagogue for the treatment of elevated serum potassium or hyperkalemia a problem among certain patients with kidney and/or heart disease; and RDX020 for adult patients with metabolic acidosis a serious electrolyte disorder. The company has agreements with Kyowa Kirin Fosun Pharmaceutical Industrial Development Co. Ltd. and Knight Therapeutics Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx Inc. and changed its name to Ardelyx Inc. in June 2008. Ardelyx Inc. was incorporated in 2007 and is headquartered in Waltham Massachusetts.
View LessARDX | US
Risk
46.1
Sharpe
0.27
Luna's Score
39/100
Recommendation
Sell
Luna says (ARDX | US)
What's Working
Strong Revenue Growth (> 10%)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
37.4%1 month
46.1%3 months
66.6%6 months
73.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
9.34
Debt to equity
0.71
Debt to assets
0.31
Ent. to EBITDA
-27.36
Ent. to rev.
6.15
PEG
-0.08
Other Fundamentals
EBITDA
-57.24M
MarketCap
1.40B
MarketCap(USD)
1.40B
Div. yield
-
Op. margin
-18.62
Erngs. growth
-
Rev. growth
227.90
Ret. on equity
-48.23
Short ratio
8.00
Short perc.
11.14
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
0.81
Range1M
1.44
Range3M
3.29
Volumes: Market Activity
Rel. volume
1.23
Price X volume
23.61M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -27.36 | - | Cheaper |
| Ent. to Revenue | 6.15 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 9.34 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 66.64 | - | Par |
| Debt to Equity | 0.71 | -1.23 | Expensive |
| Debt to Assets | 0.31 | 0.25 | Expensive |
| Market Cap | 1.40B | - | Emerging |
